Kyowa Hakko Kogyo Maps Three-Year Plan For Kidney Disease Role
This article was originally published in PharmAsia News
Kyowa Hakko Kogyo of Japan has mapped out a three-year plan designed to give it a greater presence in the market for treating kidney diseases. The plan envisions increased sales of its medical division by 10 percent during the run of the plan. Particular attention is to be given to a drug for treating renal anemia, developed by Kirin Pharma and acquired by Kyowa last fall in a merger to be completed in October. To increase sales, Kyowa plans to increase its sales force to about 1,400 representatives. The plan also calls for working with Kirin to bring antibody drugs to market. (Click here for more - a subscription may be required
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.